Eficacy and safety of atorvastatin for the treatment of nonalcoholic fatty liver disease in Chinese Han people: a randomized double-blinded placebo-controlled trial

INTERVENTION: 1:atorvastatin 40mg QD given orally;2:placebo QD given orally; CONDITION: nonalcoholic fatty liver disease PRIMARY OUTCOME: liver biopsy; SECONDARY OUTCOME: ultrasonographic exam of liver; INCLUSION CRITERIA: All patients had compensated liver diseasewith hemoglobin values of 12 g/dL or greater in females and13 g/dL or greater for males, a white blood cell countof >3000/mm3, neutrophil count >1500/mm3, platelets>70,000/mm3, albumin >3.0 g/dL, in addition to normaltotal bilirubin, prothrombin time, and Internationalnormalized ratio. Other requirements included serumcreatinine <1.4 mg/dL, and elevated serum lipid panelmanifested by either total cholesterol of >200 mg/dL,LDL >130 mg/dL, or TGs >200 mg/dL.